These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. 6α-Acetoxyanopterine: A Novel Structure Class of Mitotic Inhibitor Disrupting Microtubule Dynamics in Prostate Cancer Cells. Levrier C; Sadowski MC; Rockstroh A; Gabrielli B; Kavallaris M; Lehman M; Davis RA; Nelson CC Mol Cancer Ther; 2017 Jan; 16(1):3-15. PubMed ID: 27760837 [TBL] [Abstract][Full Text] [Related]
6. Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy. Faustino C; Francisco AP; Isca VMS; Duarte N Curr Pharm Des; 2018; 24(36):4270-4311. PubMed ID: 30636588 [TBL] [Abstract][Full Text] [Related]
7. Mitosis inhibitors in anticancer therapy: When blocking the exit becomes a solution. Henriques AC; Ribeiro D; Pedrosa J; Sarmento B; Silva PMA; Bousbaa H Cancer Lett; 2019 Jan; 440-441():64-81. PubMed ID: 30312726 [TBL] [Abstract][Full Text] [Related]
8. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs. Schmidt M; Bastians H Drug Resist Updat; 2007; 10(4-5):162-81. PubMed ID: 17669681 [TBL] [Abstract][Full Text] [Related]
9. Anti-mitotic agents: Are they emerging molecules for cancer treatment? Penna LS; Henriques JAP; Bonatto D Pharmacol Ther; 2017 May; 173():67-82. PubMed ID: 28174095 [TBL] [Abstract][Full Text] [Related]
10. Mitosis-targeting natural products for cancer prevention and therapy. Rao CV; Kurkjian CD; Yamada HY Curr Drug Targets; 2012 Dec; 13(14):1820-30. PubMed ID: 23140292 [TBL] [Abstract][Full Text] [Related]
11. Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin. Kuznetsov G; TenDyke K; Towle MJ; Cheng H; Liu J; Marsh JP; Schiller SE; Spyvee MR; Yang H; Seletsky BM; Shaffer CJ; Marceau V; Yao Y; Suh EM; Campagna S; Fang FG; Kowalczyk JJ; Littlefield BA Mol Cancer Ther; 2009 Oct; 8(10):2852-60. PubMed ID: 19825803 [TBL] [Abstract][Full Text] [Related]
12. Antimitotic drugs in cancer chemotherapy: promises and pitfalls. Marzo I; Naval J Biochem Pharmacol; 2013 Sep; 86(6):703-10. PubMed ID: 23886991 [TBL] [Abstract][Full Text] [Related]
13. Kinesin motor proteins as targets for cancer therapy. Huszar D; Theoclitou ME; Skolnik J; Herbst R Cancer Metastasis Rev; 2009 Jun; 28(1-2):197-208. PubMed ID: 19156502 [TBL] [Abstract][Full Text] [Related]
14. Advances in mitotic inhibitors for cancer treatment. Jiang N; Wang X; Yang Y; Dai W Mini Rev Med Chem; 2006 Aug; 6(8):885-95. PubMed ID: 16918495 [TBL] [Abstract][Full Text] [Related]
15. Multicomponent reactions in antimitotic drug discovery. Cores A; Carbajales C; Coelho A Curr Top Med Chem; 2014; 14(20):2209-30. PubMed ID: 25440494 [TBL] [Abstract][Full Text] [Related]
16. Microtubule destabilising agents: far more than just antimitotic anticancer drugs. Bates D; Eastman A Br J Clin Pharmacol; 2017 Feb; 83(2):255-268. PubMed ID: 27620987 [TBL] [Abstract][Full Text] [Related]
17. A Pyranoxanthone as a Potent Antimitotic and Sensitizer of Cancer Cells to Low Doses of Paclitaxel. França F; Silva PMA; Soares JX; Henriques AC; Loureiro DRP; Azevedo CMG; Afonso CMM; Bousbaa H Molecules; 2020 Dec; 25(24):. PubMed ID: 33322077 [TBL] [Abstract][Full Text] [Related]
18. Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Harrison MR; Holen KD; Liu G Clin Adv Hematol Oncol; 2009 Jan; 7(1):54-64. PubMed ID: 19274042 [TBL] [Abstract][Full Text] [Related]
19. Targeting mitosis for anti-cancer therapy. Sudakin V; Yen TJ BioDrugs; 2007; 21(4):225-33. PubMed ID: 17628120 [TBL] [Abstract][Full Text] [Related]
20. KSP inhibitors as antimitotic agents. Pérez-Melero C Curr Top Med Chem; 2014; 14(20):2286-311. PubMed ID: 25434354 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]